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ABSTRACT 
Sustained and controlled drug delivery system release the drug at a substantially steady rate of release per unit of time. However, there are instances where 
maintaining a  constant blood level of a drug is  not desirable. In such cases a  pulsatile drug delivery may be more advantageous. Pulsatile  drug delivery 
system (PDDS) is the most interesting time and site-specific  system. This system is designed for chronopharmacotherapy which is based on circadian 
rhythm. Pulsatile drug  delivery systems are gaining importance as these systems deliver the drug at specific time as per the pathophysiological need of the 
disease resulting in  improved  patient  therapeutic  efficacy  and  compliance. The current article  focuses on the need  for  pulsatile drug  delivery  system, 
diseases requiring pulsatile drug delivery system, methodologies involved for the  existing systems, application of natural polymers as drug release modifiers 
for pulsatile drug delivery systems with supportive studies on natural polymers as suitable candidates for pulsatile drug delivery systems and pulsatile drug 
delivery product currently available in the market. 
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INTRODUCTION 
A delivery system with a release profile that is characterized 
by a time period of no release (lag time) followed by a rapid 
and complete drug release (pulse release) can be called as an 
ideal  pulsatile  drug  delivery  system.  In  other  words,  it  is 
required that a drug should not be released during the initial 
phase of dosage form administration. Lag time is defined as 
the  time  between  when  a  dosage  form  is  placed  into  an 
aqueous  environment  and  the  time  at  which  the  active 
ingredient  begins to  get released  from the  dosage  form. A 
Pulsatile drug delivery system is characterized by a lag time 
that is an interval of no drug release followed by rapid drug 
release
1. A timed, pulsatile delivery system provides one or 
more rapid release pulses at predetermined lag times or at 
specific sites resulting in better absorption of the drug, and 
thereby providing more effective plasma concentration time 
profile
2. 
Merits of pulsatile drug delivery system:
 
·  Predictable, reproducible and short gastric residence time 
·  Improve bioavailability 
·  Extended day time night time activity 
·  Drug  adapts  to suit cardiac rhythms  to body function or 
disease 
·  Drug targeting to specific site like colon 
·  Protection of mucosa from irritating drugs 
Limitations of pulsatile drug delivery system: 
·  Lack of manufacturing, reproducibility and efficacy  
·  Batch manufacturing process 
·  Higher cost of production 
·  Trained/skilled personnel needed for manufacturing 
·  Low drug load 
·  Immediate withdrawal of drug is not possible 
Circadian rhythms and their implications
3,4: 
 Circadian  rhythms  are  self-sustaining,  endogenous 
oscillation, exhibiting periodicities  of about  one  day  or 24 
hrs. Normally, circadian rhythms are synchronized according 
to the body’s pacemaker clock, located in the suprachiasmic 
nucleus of the hypothalamus. 
  The  physiology  and  biochemistry  of  human  being  is  not 
constant  during  the  24  hrs,  but  variable  in  a  predictable 
manner  as defined  by the  timing  of the peak  and  through 
of  each  of  the  body’s  circadian  processes  and  functions. 
The  peak  in  the  rhythms  of  basal  gastric  and  secretion, 
white  blood  cells,  lymphocytes,  prolactin,  melatonin, 
eosinophils,  adrenal  corticotrophic  hormone  (ACTH), 
follicle  stimulating  hormone  (FSH)  and  leuteinizing 
hormone  (LH),  is  manifested  at  specific  times  during  the 
nocturnal  sleep  span.  The  peak  in  serum  cortisol, 
aldosterone,  testosterone  plus  platelet  adhesiveness  and 
blood  viscosity  follows  later  during  the  initial  hours  of 
diurnal  activity.  Hematocrit  is  the  greatest  and  airway 
caliber  the  best  around  the  middle  and  afternoon  hours, 
platelet numbers and uric acid peak later during the day  and 
evening. Hence, several physiological  processes  in humans 
vary in a rhythmic  manner,  in synchrony  with the internal 
biological clock. 
Through  a  number  of  clinical  trials  and  epidemiological 
studies, it  has become  evident  that  the  levels  of  disease 
activity  of  number  of  clinical  disorders  have  a  pattern 
associated  with  the body’s  inherent  clock  set according  to 
circadian rhythms. Infact just as the time of day influences 
normal biologic processes, so it affects the pathophysiology 
of disease and its treatment. 
Chronotherapeutic:  Therapy  in  synchrony  with 
biorhythms 
   Chronotherapy  coordinates  drug  delivery  with  human 
biological  rhythms  and  holds  huge  promise  in  areas  of 
pain  management and  treatment  of  asthma, heart  disease 
and cancer. The coordination of medical treatment and drug 
delivery with such biological clocks and rhythms is termed 
chronotherapy
5. 
   Chronotherapeutics  or  delivery  of  medication  in 
concentrations  that  vary according to physiological  need at 
different times during the dosing period; is a relatively new 
practice in clinical medicine and thus many physicians are 
unfamiliar  with  this  intriguing  area  of  medicine.  It  is 
important  that  physicians  understand  the  advantages  of 
chronotherapy  so  that  they  can  make  well-informed 
decisions  on which therapeutic  strategies  are best  for their 
patients-traditional  ones or chronotherapies. 
The  goal  of  chronotherapeutics  is  to  synchronize  the 
timing  of  treatment  with  the  intrinsic  timing  of  illness. 
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when  the right  amount  of  drug  is  delivered  to  the  correct 
target  organ  at  the  most  appropriate  time.  In  contrast, 
many  side  effects  can  be  minimized  if  a drug is not given 
when it is not needed. 
Need for pulsatile drug delivery system
6 
There  are  many  conditions  and  diseases  where  sustained 
release formulations do not show good efficacy.  
The  shift  from  conventional  sustained  release  approach  to 
modern  pulsatile  delivery  of  drugs  can  be  credited  to  the 
following reason(s): 
1. Chronopharmacological need 
2. Biological tolerance 
3. Gastric irritation or drug instability in gastric fluid 
4. Local therapeutic need 
5. First pass metabolism 
Classification of pulsatile drug delivery system 
Methodologies for the pulsatile drug delivery system can be 
broadly classified as following three types
7: 
I.  Time controlled pulsatile release system 
II.  Stimuli induced pulsatile release system 
III. External stimuli pulsatile release 
I. Time controlled pulsatile release system:  
These time-controlled systems can be classified as single unit 
(e.g., tablet or capsule) or multiple unit systems.  
A. Single unit systems 
B. Multi-particulate systems 
A. Single unit system 
i) Pulsatile system based on capsule: 
   A  general  architecture  of  such  systems  consists  of  an 
insoluble capsule body housing a drug and a plug. The plug is 
removed after a predetermined lag time owing to swelling, 
erosion, or dissolution. Manipulating the dimension and the 
position of the plug can control the lag time. 
ii) Port system: 
  The Port
® system
 consists of a gelatin capsule coated with a 
semipermeable membrane (e.g., cellulose acetate) housing an 
insoluble plug (e.g., lipidic) and an osmotically active agent 
along with the drug formulation. Coating thickness controls 
the lag time.   
iii) Delivery by a series of stops: 
This  system  is  described  for  implantable  capsules.  The 
capsule  contains  a  drug  and  a  water-absorptive  osmotic 
engine  that  are  placed  in  compartments  separated  by  a 
movable  partition.  The  pulsatile  delivery  is  achieved  by  a 
series of stops along the inner wall of the capsule.  
iv) Delivery by solubility modulation: 
  These  systems  contain  a  solubility  modulator  for  pulsed 
delivery  of  variety  of  drugs.  The  compositions  contain  the 
drug and a modulating agent, sodium chloride (NaCl). The 
amount of NaCl was such that it was less than the amount 
needed  to  maintain  saturation  in  a  fluid  that  enters  the 
osmotic  device.  The  pulsed  delivery  is  based  on  drug 
solubility. 
v)  Delivery  by  reservoir  systems  with  erodible  or  soluble 
barrier coatings: 
  Most  of  the  pulsatile  drug  delivery  systems  are  reservoir 
devices  coated  with  a  barrier  layer.  Barrier  erodes  or 
dissolves  after  a  specific  lag  period,  and  the  drug  is 
subsequently released rapidly. The time lag depends on the 
thickness of the coating layer. 
B. Multiparticulate systems: 
  Multi-particulate  drug  delivery  systems  are  mainly  oral 
dosage  forms  consisting  of  a  multiplicity  of  small discrete 
units, in which the active substance is present as a number of 
small independent subunits. 
  There are different types of multiparticulate systems and these 
are enumerated and explained below: 
  i) Pulsatile system based on rupturable coating: 
  This is a multiparticulate system in which drug is coated on 
non-pareil sugar seeds followed by a swellable layer and an 
insoluble  top  layer.  The  release  is  independent  of 
environmental factors like pH and drug solubility. The lag 
time can be varied by varying coating thickness or adding 
high amounts of lipophilic plasticizer in the outermost layer. 
ii) Time controlled expulsion system: 
  This  system  is  based  on  a  combination  of  osmotic  and 
swelling  effects.  The  core  contains  the  drug,  a  low  bulk 
density solid and/or liquid lipid material (e.g., mineral oil) 
and a disintegrant. The core is further coated with cellulose 
acetate.  
iii) Sigmoidal release system: 
  This consists of pellet cores comprising drug 
and  succinic  acid  coated  with  ammonia- 
methacrylate  copolymer  USP/NF  type  B.  The  time  lag  is 
controlled by the rate of  water influx through the polymer 
membrane. The water dissolves acid and the drug in the core. 
The  acid  solution  in  turn  increases  permeability  of  the 
hydrated polymer film. 
iv) Low density floating multiparticulate pulsatile systems: 
  Low density floating multiparticulate pulsatile dosage forms 
reside only in stomach and not affected by variability of pH, 
local  environment  or  gastric  emptying  rate.  These  dosage 
forms  are  also  specifically  advantageous  for  drugs  either 
absorbed  from  the  stomach  or  requiring  local  delivery  in 
stomach.  
II. Stimuli induced pulsatile release system: 
  The mechanisms of drug release include ejection of the drug 
from the gel as the fluid phase synerges out, drug diffusion 
along  a  concentration  gradient,  electrophoresis  of  charged 
drugs towards an oppositely charged electrode and liberation 
of the entrapped drug as the gel or micelle complex erodes.  
It further includes chemical stimuli induced pulsatile systems 
subclassified into the following: 
i)   Glucose-responsive insulin release devices 
ii)  Inflammation-induced pulsatile release 
iii) Drug release from intelligent gels responding to antibody 
concentration 
III. External stimuli pulsatile release:  
This  system  is  not  self-operated,  but  instead  requires 
externally generated environmental changes to initiate drug 
delivery.  These  can  include  magnetic  fields,  ultrasound, 
electricfield, light and mechanical force. It include: 
i)  Electro responsive pulsatile release 
ii) Magnetically induced pulsatile release 
Natural polymers as release modifiers for pulsatile drug 
delivery system
8,9,10: 
Polymers have been successfully investigated and employed 
in  the  formulation  of  solid,  liquid  and  semi-solid  dosage 
forms and are specifically useful in the design of novel drug 
delivery  systems.  Synthetic  polymers  are  toxic,  expensive, 
have environment related issues, need long development time 
for  synthesis  and  are  freely  available  in  comparison  to 
naturally  available  polymers.  However  the  use  of  natural 
polymers  for  pharmaceutical  applications  is  attractive 
because they are economical, readily available, non-toxic and 
capable of chemical modifications, potentially biodegradable 
and with few exceptions and also biocompatible. 
A large number of plant-based pharmaceutical excipients are 
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available  today.  Many  researchers  have  explored  the 
usefulness  of  plant-based  materials  as  pharmaceutical 
excipients. Ability to produce a wide range of material based 
on  their properties and  molecular weight, natural polymers 
became  a  thrust  area  in  majority  of  investigations in  drug 
delivery systems. Natural gums can also be modified to meet the 
requirements of drug delivery systems and thus can compete 
with the synthetic excipients available in the market. 
The  plant  based  polymers  have  been  studied  for  their 
application  in  different  pharmaceutical  dosage  forms  like 
matrix controlled system, film coating agents, buccal films, 
microspheres, nanoparticles, viscous liquid formulations like 
ophthalmic  solutions,  suspensions,  implants  and  their 
applicability  and  afficacy  has  been  proven. These  has  also 
been utilized as viscosity enhancers, stabilisers, disintegrants, 
solubilisers,  emulsifiers,  suspending  agents,  gelling  agents 
and  bioadhesives,  binders  in  the  above  mentioned  dosage 
forms. 
Some  natural  polymers  selected  as  suitable  candidates  for 
PDDS  are:  Karaya  gum,  tragacanth  gum,  copal  gum, 
tamarind  seed  polymer,  locust  bean  gum,  dammar  gum, 
xanthan gum, gaur gum, chitosan etc. 
Vidyadhara S, Prasad SS, Devi VA, Chowdary YA
11 have 
developed  an  oral  monolithic  controlled  dosage  form  of 
diltiazem  hydrochloride  with  dammar  gum  as  controlled 
release  polymer.  In  the  present  study,  the  influence  of 
different  concentrations  of  polymer  on  erosion  of  matrix 
system  was  studied,  with  a  view  to  develop  slow  release 
formulation  of  diltiazem  hydrochloride.  The  diltiazem 
hydrochloride  matrix  tablets  were  prepared  by  direct 
compression  and  wet  granulation  methods.  Various 
formulations  were  prepared;  DTZ-1  to  DTZ-6.  The results 
from  the  in-vitro  drug  release  studies  indicated  that,  the 
formulations  DTZ-5  and  DTZ-6  with  drug:  polymer 
concentrations, 1:1 and 1:1.5 respectively, prepared by  wet 
granulation  method  using  distilled  water  as  solvent  were 
found to release the drug at a steady state over an extended 
period of time up to 12 hours. 
Selvam G, Ashutosh KP, Jeyakandan M, Ashok KM
12 carried 
out studies on formulation and evaluation of chitosan matrix 
tablets of tinidazole. The study consist of sustained release 
matrix  tablets  of  tinidazole  with  chitosan  in  different 
proportions  (1:0.1,  1:0.15,  1:0.2)  prepared  by  wet 
granulation  method  using  EC, CAP, HPMCP  and shellac 
solutions. 12 formulations were prepared TE-1 to TE-3, TC-1 
to TC-3, THP-1 to THP-3, TS-1 to TS-3. It was observed that 
the  integrity  of  the  drug  is  not  affected  by  formulation 
procedure. The  result revealed  that  the  drug  polymer  ratio 
(i.e. THP-1; 1:0.1) showed a greater drug release than other 
formulations. 
Chavda  HV,  Patel  MS,  Patel  CN
13  have  designed  an  oral 
controlled drug delivery system for diclofenac sodium using 
guar  gum  as  triple-layer  matrix  tablets.  The  design  of  the 
study was as follows; matrix tablet granules containing 30% 
(D1),  40% (D2) or 50% (D3) of guar gum  were  prepared 
by wet granulation technique.  Matrix  tablets  of  diclofenac 
sodium were  prepared by  compressing three layers  one  by 
one. Centre layer of sandwich like structure was incorporated 
with  matrix  granules  containing  diclofenac  sodium  which 
was  covered  on  either  side  by  guar  gum  granule  layers 
containing  either  70,  80  or  87%  of  guar  gum  as  release 
retardant  layers.  D3, containing 87%  of  guar gum in  guar 
gum  layers  and  50%  of  guar  gum  in  diclofenac  sodium 
matrix granule layer was found to provide the release rate for 
prolonged  period  of  time.  The  results  clearly  indicate  that 
guar  gum  could  be  a  potential  hydrophilic  carrier  in  the 
development of oral controlled drug delivery systems. 
Vishnumurthy V, Dheeraj N
14 have formulated and evaluated 
sustain release tablets of frusemide using natural hydrophilic 
polymers  like  Guar  gum,  Pectin,  Tragacanth  gum  and 
Xanthan  gum.  The  study  consist  of  total  16  formulations 
prepared  using  different  quantities  of  Guar  gum,  Pectin, 
Tragacanth gum and Xanthan gum; formulations G1 to G4, 
P1 to P4, T1 to T4, X1 to X4. Result of  the present study 
ascertains  that  natural  gums  employed  were  found  to  be 
successful  in  formulating  the  sustained-release  matrix 
tablets  of  Frusemide.  It  was  evident that the concentration 
of gums upto 47% was capable of prolonging the release of 
drug for 16hrs. Among the natural gums used, Guar gum was 
found to be more effective than others in sustaining the drug 
release.  The  observed  sustaining performance order  was as 
follows:  Guar  gum  >  Xanthan  gum  >  Tragacanth  gum  > 
Pectin. 
 
Table 1: Circadian rhythm and manifestation of Clinical diseases
 
Disease or syndrome  Circadian rhythmicity 
Allergic Rhinitis  Worse in the morning/ upon rising 
Asthma  Exacerbation more common during the sleep period 
Angina Pectoris  Chest pain and ECG changes more common in early  morning 
Myocardial Infraction  Incidence greatest in early morning 
Osteoarthritis  Symptoms worse in the middle/ later portion of the day 
Peptic ulcer disease  Worse in late evening and early morning hours 
Rheumatoid Arthritis  Increased stiffness early in the morning which typically lasts for more than an hour and decrease later in day 
Sudden cardiac death  Incidence higher in the morning after awakening 
Stroke  Incidence higher in the morning 
 
Table 2: Diseases requiring Pulsatile drug delivery 
Diseases  Chronological behaviour  Drugs used 
Arthritis  Pain in the morning and more  pain in the night  NSAIDs, Glucocorticoids 
Asthma  Precipitation of attacks during night or at early morning hours  β2 agonist, Antihistaminics 
Attention deficit syndrome  Increase in DOPA level in noon  Methylphenidate 
Cardiovascular diseases  BP is at its lowest during sleep cycle and rises steeply during early 
morning awakening period 
Nitroglycerin, Calcium channel blocker, 
ACE inhibitors etc 
Diabetes mellitus  Increase in blood sugar level after meal  Sulfonylurea, Insulin, Biguanide 
Hypercholesterolemia  Cholesterol synthesis is generally higher during night than day  HMG CoA reductase inhibitors 
Peptic ulcer  Acid secretion is high in the noon and at night  H2 blockers 
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Table 3: Marketed technologies of Pulsatile drug delivery system 
Technology  Mechanism  API  Disease 
Pulsys®  Timed-controlled System  Amoxicillin  Pharyngitis/Tonsillitis 
Uniphyl®  Externally regulated System  Theophylline  Asthma 
Ritalina®  Osmotically Regulated  Methyl Phenidate  Attention deficit hyperactivity     disorder 
Opana®ER  Timed-controlled System  Oxymorphone  Pain medicine 
TheirForm®  Externally regulated  System  Diclofenac sodium  Inflammation 
 
 
 
Figure 1: Schematic diagram of circadian rhythm showing diseases require pulsatile drug delivery system 
 
CONCLUSION 
Circadian  rhythm  of  the  body  is  an  important  concept  for 
understanding  the optimum  need of drug in the body. There 
is a constant need for new delivery systems that can provide 
increased therapeutic benefits to  the  patients.  Pulsatile drug 
delivery is  one such system that,  by delivering drug at the 
right  time,  right  place  and  in  right  amounts,  holds  good 
promises  of  benefit  to  the  patients  suffering  from  chronic 
problems  like  arthritis,  asthma,  hypertension  etc.  Thus 
designing of proper pulsatile  drug  delivery  will enhance  the 
patient compliance, optimum drug delivery to the target site 
and  minimize the  undesired effects.  The approaches in this 
article  represent  application  of  natural  polymers  as  drug 
release  modifiers  with  a  view  to  design  pulsatile  drug 
delivery systems keeping in mind the toxic effects of the 
drugs incorporated and to maintain the overall stability of 
the  product  on  account  of  the  properties  of  natural 
polymers.  There  are  various  technologies  present  in  the 
market based on the various methodologies. Pulsatile release 
systems  with  natural  polymers  as  drug  release  modifiers 
should be promising in the future. 
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